States FrontFour's Publicly Outlined Strategic Initiatives Can Deliver 120% Upside if Properly Executed Reveals a Slate of Highly-Qualified, Independent Candidates to Revitalize and Improve OM Group's Board
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology
biotechnology company, today announced that the World Health
Organization (WHO) has approved the international nonproprietary name
(INN) “entrectinib” for the company’s lead product candidate, RXDX-101.
Sign-up for Codexis Uses Its CodeEvolver(R) Protein Engineering Platform Technology to Develop an Enzyme Therapeutic Candidate for the Potential Treatment of Phenylketonuria (PKU) via Oral Administration investment picks
In Voting Overwhelmingly on Broadfin's Gold Proxy Card Shareholders Followed the Recommendations of ISS and Glass Lewis Broadfin Looks Forward to a Refreshed Board with Five Recent Additions and the Opportunity to Create Immediate Positive Impact
NEW YORK , Dec.
Sign-up for Intellipharmaceutics Reports the Signing of an Exclusive Licensing and Manufacturing Agreement With Teva Pharmaceuticals USA, Inc. for an Extended Release Oral Drug Product Candidate investment picks
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.